This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Curis (CRIS) Down on FDA Partial Clinical Hold on Lymphoma Study
by Zacks Equity Research
The FDA places a partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares fall.
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
by Zacks Equity Research
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.
The Zacks Analyst Blog Highlights Alphabet, Amazon, AbbVie, Walmart, and Toyota Motor
by Zacks Equity Research
Alphabet, Amazon, AbbVie, Walmart, and Toyota Motor are part of top Analyst Blog.
Top Analyst Reports for Alphabet, Amazon & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).
Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Great Dividend Stocks to Buy Now to Help Tackle Inflation
by Benjamin Rains
Investors might want to remain in stocks in order to beat 8% inflation, while adding strong dividend yields that top U.S. Treasuries. Here are few stocks to consider buying to do just that.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $161.89 in the latest trading session, marking a -0.49% move from the prior day.
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $161.97 in the latest trading session, marking a +0.4% move from the prior day.
Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.
2 Surging Stocks to Buy to Fight Market Volatility
by Benjamin Rains
Here are a couple strong, dividend-paying stocks to consider buying amid the current economic uncertainty and market volatility.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $160.01, moving -0.02% from the previous trading session.
Amgen (AMGN) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session.
AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment
by Zacks Equity Research
AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.
AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions
by Zacks Equity Research
AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.
AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.
Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale
by Kinjel Shah
Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, NVIDIA, AbbVie and HSBC Holdings
by Zacks Equity Research
Microsoft, Amazon.com, NVIDIA, AbbVie and HSBC Holdings are included in this blog.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.
What's in Store for These 3 Big Pharma Outperformers in 2022?
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Top Analyst Reports for Microsoft, Amazon & NVIDIA
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and NVIDIA Corporation (NVDA).
AbbVie (ABBV) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $149.45, marking a -0.74% move from the previous day.